Nvax (Nasdaq). «Creating tomorrow’s vaccines today». Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
In April 2017 I published an article about Novavax, from that date I bought and sold the stocks of the company several times, but without success. Then in 2020 at the start of the Covid pandemic it raised from 5$ to 290$ at the beginning of 2021, but unfortunately since I had others problems I didn’t buy it.
In the meantime the company has changed a lot, and on May 10, 2024 Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines.
This is the new profile of the company.
We are a biotechnology company, with more than 1,545 employees, committed to helping to address serious infectious diseases globally through the discovery, development and delivery of innovative vaccines to patients around the world. We never rest in our quest to protect the health of people everywhere.
Novavax is here to make a difference. We’re a biotech company focused on developing life-saving vaccines to fight infectious diseases. We use solid science tested by decades of research to develop vaccines. We seek and encourage meaningful partnerships and collaborations with leading biopharma organizations, research institutions, government agencies and foundations.
The power & speed of nanoparticle technology
Our vaccine technology combines power and speed with the immunogenicity-enhancing properties of our Matrix-M™ adjuvant to efficiently produce highly immunogenic particles targeting some of the most pressing viral infectious diseases.
Our people & culture
Our team is experienced, compassionate, and focused on the future of vaccine development. While growing rapidly, we maintain that small company culture.
Our Partners
We seek and encourage meaningful partnerships and collaborations with leading biopharma organizations, research institutions, government agencies and foundations.
Novavax in Europe
Novavax AB
Novavax AB is headquartered in Uppsala, Sweden. This site is responsible for the research, development and manufacturing of our saponin adjuvants. Our Matrix-MTM is used in several vaccine candidates to enhance the immune response and stimulate high levels of neutralizing antibodies.
Novavax CZ
In 2020, Novavax CZ was established, located in Bohumil, Czech Republic. This facility is an advanced biologics and vaccine manufacturing campus dedicated to the production of vaccines to protect global health.
Novavax EU
Since 2022, Novavax has started to develop its commercial hubs across Europe with its main regional headquarters in Zurich, Switzerland. Additional locations have been established in Brussels, Belgium and Barcelona, Spain.
Our Headquarters:
Novavax CH GmbH
Fraumünsterstrasse 16
8001 Zürich
Switzerland
Novavax (NVAX) Website: https://www.novavax.com is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this vaccine maker have returned -21.2% over the past month versus the Zacks S&P 500 composite’s +4.5% change. The Zacks Medical – Biomedical and Genetics industry, to which Novavax belongs, has lost 1.5% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company’s business prospects usually make its stock ‘trending’ and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
While earnings growth is arguably the most superior indicator of a company’s financial health, nothing happens as such if a business isn’t able to grow its revenues. After all, it’s nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it’s important to know a company’s potential revenue growth.
In the case of Novavax, the consensus sales estimate of $57.32 million for the current quarter points to a year-over-year change of -69.3%. The $773 million and $475.5 million estimates for the current and next fiscal years indicate changes of -21.4% and -38.5%, respectively.
This is a part of the old article.
Novavax Inc. is based out of Garthersburg, MD and has some 355 employees. Its CEO is Stanley Charles Erck. Novavax Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
We are also developing proprietary technology for the production of immune stimulating saponin-based adjuvants through our wholly owned Swedish subsidiary, Novavax AB. Our lead adjuvant, Matrix-MTM, has been successfully tested in a Phase 1/2 clinical trial for our pandemic H7N9 influenza virus-like particle (VLP) vaccine candidate, and in a Phase 1 clinical trial for our EBOV vaccine candidate. Genocea Biosciences, Inc. (Genocea) has licensed rights to our Matrix technology and has conducted Phase 2 clinical trials with its herpes simplex 2 vaccine candidate using Matrix-M.
Novavax was incorporated in 1987 under the laws of the State of Delaware. Our principal executive offices are located at 20 Firstfield Road, Gaithersburg, Maryland, 20878. Our telephone number is (240) 268-2000 and our website address is www.novavax.com.
In 2015, Novavax received a grant from the Bill & Melinda Gates Foundation to develop its vaccine in certain low and middle income countries as part of the development of its RSV F Vaccine for maternal immunization. The Bill & Melinda Gates Foundation has awarded Novavax up to $89 million to support development of the RSV F Vaccine Phase 3 clinical trial in pregnant women, planned to initiate during the first quarter of 2016. This grant will also support regulatory licensing efforts, providing a path to World Health Organization (WHO) prequalification. Upon licensure, Novavax has agreed to make the RSV F vaccine affordable and accessible to people in the developing world.
In March 2015 the company completed a Phase I trial for its Ebola vaccine candidate.
In September 2016 the company announced that a Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall from $8.34 to $1.40 and led the company to lay off 30% of its employees.
As of November 2016 its RSV F vaccine candidate was in three clinical trials.
Financial Summary
BRIEF: For the fiscal year ended 31 December 2016, Novavax, Inc. revenues decreased 58% to $15.4M. Net loss increased 78% to $280M. Revenues reflect Government contracts decrease of 93% to $2.2M. Higher net loss reflects General and administrative – Balancing increase of 59% to $38.5M (expense), Interest Expense increase from $241K to $13M (expense), Labor & Related Expenses in R&D increase of 65% to $11.2M (expense).
Gaithersburg vaccine company Novavax Inc. saw its share price jump at least 26 percent Tuesday – coming within a penny of the $1 threshold for the first time in a month – following its report of narrowed first-quarter losses.
Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.
Top Master Trading Links and Resources
Market, financial, business news
Money, wealth, investments news
Jesse Livermore trading lessons
The true words of Jesse Livermore
50 Famous Quotes by Jesse Livermore
